{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-0bfb-77a4-9766-824e83d61c36", "slug": "78f42e9d8d70fea2dc2370a17955f7e7", "title": "Nuvalent | Investor Presentation Deck | 52 slides", "subtitle": "Nuvalent · 2023-10", "author": "Nuvalent", "date": "2023-10-01 00:00:00", "pageCount": 52, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-0bfb-77a4-9766-824e83d61c36", "slug": "78f42e9d8d70fea2dc2370a17955f7e7", "title": "Nuvalent | Investor Presentation Deck | 52 slides", "rawTitle": "Nuvalent | Investor Presentation Deck | 52 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "authorDisplay": "Nuvalent", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-10__nuvalent__investor-pres__78f42e9d.pdf", "sourceUrl": "https://www.slidebook.io/company/nuvalent/presentation/78f42e9d8d70fea2dc2370a17955f7e7/", "sourceDate": "2023-10-13 00:00:00", "presentationDate": "2023-10-01 00:00:00", "ingestedAt": "2026-04-30 22:15:26.048668+00", "status": "ready", "pageCount": 52, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-10__nuvalent__investor-pres__78f42e9d", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 52, "pagesIndexed": 52, "pagesWithImages": 52, "pagesWithMetadata": 52, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 247, "chartCount": 23, "metricSlides": 0, "toolMatches": 30, "documentToolMatches": 0, "frameworkMatches": 11, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "evidence": "The presentation deck follows a similar structure to the Sequoia Pitch, with sections on problem, solution, market sizing, competitive analysis, traction, and pipeline expansion.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:38:43.817061+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Problem", "beatId": "65550cb5-ee81-4f95-bbe3-0e8a0687e1c8", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 7: Problem statement - Structural innovations designed to overcome drug-resistance due to kinase mutations", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Solution", "beatId": "53237490-10fa-4f84-a15b-425ad3751d71", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slide 6: Solution - Precisely Targeted Therapies for patients with cancer", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Market Sizing", "beatId": "1bb8c0b5-57e2-4bb0-9d13-ed06ee6a7e1a", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slide 10: ROS1-positive NSCLC Market Overview", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3ea40440-9f86-47ed-9119-8e451211cca0", "evidence": "The slide is titled 'PRECISELY Targeted Therapies for patients with cancer' and features a clear action title.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:16.965731+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1758b4af-842b-4c84-a76a-4d0a59475ddf", "evidence": "The slide provides a brief overview of the company's progress and goals.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.067504+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "aac49ad8-c621-4082-930b-e9e21d4e639c", "evidence": "Significant Experience in Drug Discovery, Development and Company Building", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:22.623813+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e840cf15-3593-465f-abd1-efeae0eacebc", "evidence": "diagram/venn: Kinase Resistance and Kinase Selectivity intersection", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:34:17.662268+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "38a8d6aa-4ad3-4082-ae89-2e6ea02ae249", "evidence": "paragraph/paragraph: Structural innovations designed to overcome drug-resistance due to kinase mutations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.727095+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0c6867bf-82da-4641-bb34-f4995ee6f365", "evidence": "diagram/other: Comparison of non-selective vs selective therapy mechanisms", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.790989+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "04b8175b-2096-438a-b3d9-88440fa24f94", "evidence": "table/data: Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.887996+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9ec700cc-ed64-4de6-a729-abd6041a02a6", "evidence": "table/data: Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 criteria.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.954103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "aee419b0-211d-418b-aff6-18702ded8a5d", "evidence": "paragraph/paragraph: ROS1 and ALK both share strong structural similarities to TRK.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.018966+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "c1adb716-9384-4bba-9e43-f1e970435869", "evidence": "chart/bar-vertical: In vivo efficacy tumor regression bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.085148+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "81ad9521-ac58-449d-a266-66db47ad14c1", "evidence": "chart/dot: Resistance Mutations IC50 dot plot", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.117342+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "dd89f82e-245e-45fc-8d12-0d521488c7d4", "evidence": "chart/bar-grouped: Selectivity Index for ROS1 vs TRK across multiple inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.182863+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "9d768201-cb04-4f51-9d4f-35270825b7d9", "evidence": "chart/bar-vertical: Unbound brain:plasma ratio for NVL-520 vs Lorlatinib", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.216267+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0c0dce42-2003-41e2-b808-0fb0d319e703", "evidence": "table/data: Patient characteristics and treatment history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:18.346036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a6935f66-e6d5-4bf7-b351-3e73ba546ab0", "evidence": "table/data: Treatment-Related Adverse Events (TRAEs) in >1 Patient All Treated Patients (N = 35)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.746382+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "58b599fe-3d64-4933-8ab4-d404f133acdf", "evidence": "chart/line: NVL-520 concentration over time by dose cohort", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.832424+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b20d9084-a3d4-4f63-8a0f-2cefcd033a4d", "evidence": "table/data: Table showing patient counts and response rates (ORR, PR, SD, PD, NE) across 5 patient cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.918395+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8fe818ab-c533-45bb-9846-78042b84d805", "evidence": "chart/waterfall: Waterfall plot of best % change in target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:18.005564+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6e7a0e43-7037-410f-a0d6-a86271a66d51", "evidence": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:34:22.458103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "64a791cd-34bf-4b63-acf8-fccda1093873", "evidence": "In vivo tumor regression bar chart comparing Vehicle, Lorlatinib, and NVL-655", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:22.544326+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "7a88634f-476c-4f97-8db2-21f6c4cf2a7b", "evidence": "In vitro IC50 scatter plot comparing NVL-655 to other inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:22.630075+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3839ecf4-dd08-4d23-ac9f-b6ad983f0cc9", "evidence": "Clearance of ALK Mutations Detected in Plasma", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:22.931747+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b772db01-226a-42f4-b3f4-590040855188", "evidence": "Waterfall plot of tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:23.061257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fa1b8c13-1632-439a-91c0-3099b338aeed", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:28.943337+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 42, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "a4a8fdb0-6970-4bde-98c7-146078e5ab61", "evidence": "Baseline and 20 weeks CT scans", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.037817+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 44, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "AIDA Model", "slug": "aida-model", "status": "active", "bestFor": null, "canonId": "019dd956-86fc-773c-813f-d416714b8413", "version": 1, "bodyDocId": null, "description": "Attention, Interest, Desire, Action - classic persuasion sequence", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "c75ec5d2-d5d1-4c81-9d66-515cb102c593", "evidence": "This preliminary dataset indicates encouraging clinical activity... with responses observed in patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:34:29.10207+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "6ffab56d-b5d0-478b-8a6d-e72f32e7fb9f", "evidence": "IN VITRO ACTIVITY, HER2 AND HER2ex20, AVOIDING EGFR INHIBITION, BRAIN PENETRANCE", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.201644+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 47, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "94e0cd6a-c200-4139-af31-8e3a40f1287b", "evidence": "Three-step hexagonal process flow", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.30019+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 49, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "92fb98c5-d289-4fe8-9bb7-6dd980761457", "evidence": "Robust development pipeline leveraging established approach", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:29.397271+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 51, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "d8270b7f-e511-4554-a797-82fa87d701e4", "evidence": "PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:29.461248+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 52, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "17a615bc-3d27-466a-a0a6-7c4e5557871a", "evidence": "Venn diagram showing intersection of Kinase Resistance and Kinase Selectivity", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "venn" }, { "matchId": "3c5ae9b2-ec04-46fa-9d5f-7303c4904b54", "evidence": "Contrasts the state of 'existing therapy' failure against 'Nuvalent therapy' success in the context of mutation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "before-after-bridge" }, { "matchId": "0c832cbf-22c1-4e98-a29c-94d2c33a12df", "evidence": "Visual side-by-side comparison of two therapeutic approaches", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison-frame" }, { "matchId": "1f6251ff-1208-4845-a800-a95cf462103c", "evidence": "The slide presents a structured grid comparing a lead product candidate against competitors across specific attributes.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_table" }, { "matchId": "51b1150b-6902-462a-aec2-054989d30106", "evidence": "Side-by-side layout comparing Phase 1 and Phase 2 trial parameters.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "comparison-frame" }, { "matchId": "33eddfb5-0077-4b16-affc-67cfcf58d750", "evidence": "Chronological treatment history list", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "timeline-item" }, { "matchId": "aaa78935-adb7-4c93-99a1-f4fcb2bf0113", "evidence": "Grid-based comparison of product features against competitors", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "comparison_table" }, { "matchId": "88ad70a3-dad0-4482-afe5-820896f76479", "evidence": "Structured presentation of study phases, cohorts, and objectives.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "frameworkName": "clinical-trial-design" }, { "matchId": "596f8754-9649-42c2-937e-0396439d93cc", "evidence": "The slide uses a flow-based diagram to show the progression of patient cohorts through different trial stages.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "process" }, { "matchId": "af407c93-b346-4f54-add0-d67a7fd0ec9b", "evidence": "Sequential hexagonal flow diagram", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 49, "frameworkName": "process" }, { "matchId": "b4f65386-a8c4-47a3-ac0e-4a67852b4b88", "evidence": "Visual representation of project phases over time for multiple programs.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 50, "frameworkName": "gantt-chart" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/VFcfFJ4StEDNzlj5q9Mvz408jD6hCaIiAnOXNwkT8kE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83OGY0MmU5ZDhkNzBmZWEyZGMyMzcwYTE3OTU1ZjdlNy9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 31, "componentCount": 5, "textChars": 128, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.801+00", "seconds": 5.033, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/1", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-1", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.35, "x": 0.6, "y": 0.1 }, "kind": "image", "text": "Molecular structure visualization", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "636fecab-416d-49aa-8851-9069f9723ab6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.05, "y": 0.15 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac5d90f0-7b90-4d9c-896b-56abc8b6796d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.55 }, "kind": "paragraph", "text": "October 13, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cb565fd-fa22-4495-a4a6-c8bf0fff7295", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.3, "y": 0.85 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f978ed29-0f4c-4fd9-9af6-0c0b994ab948", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Corporate Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52653ad0-cab8-4c63-a169-6091eadb8123", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3ea40440-9f86-47ed-9119-8e451211cca0", "evidence": "The slide is titled 'PRECISELY Targeted Therapies for patients with cancer' and features a clear action title.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:16.965731+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/XhtshqoS5lQ_UO-X_wpD5wQoEONPruELHlsA9dQeDhw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83OGY0MmU5ZDhkNzBmZWEyZGMyMzcwYTE3OTU1ZjdlNy9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/dptAw_JNOpqPgLSglMiLqCcI-vA6-4DlfpnQyUo2oDE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83OGY0MmU5ZDhkNzBmZWEyZGMyMzcwYTE3OTU1ZjdlNy9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/TCSVHUFnu_HaC8XXWibpxYe8tKvPC7DXMM61guqFj9w/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83OGY0MmU5ZDhkNzBmZWEyZGMyMzcwYTE3OTU1ZjdlNy9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 15, "componentCount": 2, "textChars": 209, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.006+00", "seconds": 3.888, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/2", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-2", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.685, "w": 0.848, "x": 0.076, "y": 0.211 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995... [full text of disclaimer]", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c1415f4-ba7a-4d81-ba16-18348e0c3dd4", "parentComponentId": null }, { "bbox": { "h": 0.028, "w": 0.635, "x": 0.076, "y": 0.135 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb88b8a9-935d-461f-aba4-69d5f22dc4b1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a visual bracket system to connect the core mission statement to three pillars.", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 433, "nDataPoints": 0, "notes": "The slide uses a visual bracket system to connect the core mission statement to three pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:37.925+00", "seconds": 2.734, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/3", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-3", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.25, "x": 0.12, "y": 0.52 }, "kind": "list", "text": "Chemistry at the core: Expertise in chemistry and structure-based drug design drives wholly-owned pipeline of novel targeted therapies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.925+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40b46eb7-08d1-4a32-b7af-9b434d00a2fb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.65, "y": 0.52 }, "kind": "list", "text": "Driven by Purpose: Precisely designed solutions aiming to overcome limitations of existing therapies identified through close collaboration with physician-scientists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.925+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46f834aa-c49d-4046-8bf2-cbbbd900e654", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.18, "x": 0.41, "y": 0.52 }, "kind": "list", "text": "Built for Patients: Our mission is to bring new medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.925+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1a5b378-8171-4ac3-ad17-895507381b6c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.08, "y": 0.185 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.925+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b7ac436e-e7e0-49eb-afde-f3e204c0a6fd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "Slide 4 of a pitch deck.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 7, "textChars": 716, "nDataPoints": 2, "notes": "Slide 4 of a pitch deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:38.117+00", "seconds": 2.86, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/4", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-4", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.27, "x": 0.65, "y": 0.39 }, "kind": "callout", "text": "Discover, Develop & Deliver", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd92198e-2b48-4357-82d9-4c9c29980726", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.715, "y": 0.85 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67116bee-cccb-4702-835b-de60ac1531a2", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.42, "x": 0.07, "y": 0.21 }, "kind": "list", "text": "ARROS-1: RP2D selected and enrollment in Phase 2 initiated with updated data expected at a medical meeting in 2024. ALKove-1: Preliminary Phase 1 dose-escalation data presented at AACR-NCI-EORTC 2023. NVL-330: 3rd development candidate in IND-enabling studies.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2034f5f0-5b19-4734-a96d-61506f36bb96", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.42, "x": 0.07, "y": 0.64 }, "kind": "paragraph", "text": "Continued advancement of internal research & discovery pipeline. Continued team growth (75+ FTEs). $264.5M upsized financing completed in November 2022 and expected to extend cash runway into 2nd half of 2025", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6047af23-1234-40cc-b47f-df25ca13977b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.34, "x": 0.615, "y": 0.495 }, "kind": "paragraph", "text": "Fully integrated pharmaceutical company with the goal of translating deep expertise in chemistry & structure-based drug design into best-in-class small molecule medicines for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dbb3a2f1-02bb-462a-91f5-0f519e398622", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.1, "x": 0.733, "y": 0.318 }, "kind": "title", "text": "Vision", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53b1304c-eef2-4f80-bff5-7156dce9d37a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.18, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "At a glance:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8412de6d-7f0f-45cd-9e3e-ad15732c67e7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1758b4af-842b-4c84-a76a-4d0a59475ddf", "evidence": "The slide provides a brief overview of the company's progress and goals.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.067504+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "Includes a grid of headshots for the leadership team and lists for board members and advisors.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 5, "textChars": 199, "nDataPoints": 0, "notes": "Includes a grid of headshots for the leadership team and lists for board members and advisors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:37.931+00", "seconds": 2.669, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/5", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-5", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.48, "x": 0.075, "y": 0.25 }, "kind": "image", "text": "Leadership team headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "139d09a1-03f0-440c-8824-a82e6eb1cda6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.31, "x": 0.24, "y": 0.82 }, "kind": "image", "text": "Prior FDA approval experience logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ab23836-d6c5-4d3e-aecb-e7bd41cc2b83", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.35, "x": 0.58, "y": 0.25 }, "kind": "list", "text": "Board of Directors and Scientific Advisors lists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac78ee13-58a0-4d9b-b364-dcfa4f589cd4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.075, "y": 0.18 }, "kind": "title", "text": "Significant Experience in Drug Discovery, Development and Company Building", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85ee13a6-d50d-449f-8b71-82df8e3052ea", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.075, "y": 0.11 }, "kind": "title", "text": "The Nuvalent Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:37.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c702867-6337-4226-b38d-bca966297f8a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "aac49ad8-c621-4082-930b-e9e21d4e639c", "evidence": "Significant Experience in Drug Discovery, Development and Company Building", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:39:22.623813+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 598, "nDataPoints": 0, "notes": "Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:38.221+00", "seconds": 2.72, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/6", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-6", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.45, "x": 0.5, "y": 0.1 }, "kind": "diagram", "text": "Kinase Resistance and Kinase Selectivity intersection", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Venn diagram", "slug": "venn", "status": "active", "canonId": "019de52d-0463-710d-b529-cce18d828d2f", "version": 1, "description": null }, "framework": null }, "subkind": "venn", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2a7686f-04b7-4e72-a213-539b11758e48", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.07, "y": 0.55 }, "kind": "list", "text": "Expertise in structure-based drug design to create innovative small molecules\nThreading the needle: Aim to achieve high affinity for drug-resistant kinases while avoiding off-target kinases in the central nervous system (CNS) and in the periphery\nPotential to minimize adverse events AND drive more durable responses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "370256d0-0020-4e9d-b651-3cb69c9f3bcf", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.07, "y": 0.35 }, "kind": "paragraph", "text": "Nuvalent is focused on creating precisely targeted therapies to overcome key limitations of existing therapies for clinically proven kinases and renew hope for patients in need", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ea8d797-360b-471a-b0ad-834a8c7eb0cb", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.07, "y": 0.12 }, "kind": "title", "text": "Precisely Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f53f6f77-449d-4a8b-be8d-5c2ef07d75d1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e840cf15-3593-465f-abd1-efeae0eacebc", "evidence": "diagram/venn: Kinase Resistance and Kinase Selectivity intersection", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:34:17.662268+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "17a615bc-3d27-466a-a0a6-7c4e5557871a", "evidence": "Venn diagram showing intersection of Kinase Resistance and Kinase Selectivity", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:38.221+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "venn" } ], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Solution", "beatId": "53237490-10fa-4f84-a15b-425ad3751d71", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slide 6: Solution - Precisely Targeted Therapies for patients with cancer", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "tension", "title": "Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 250, "nDataPoints": 0, "notes": "Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:38.149+00", "seconds": 2.617, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/7", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-7", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.6, "x": 0.3, "y": 0.18 }, "kind": "diagram", "text": "Original tumor evolving into drug-resistant tumor via mutation", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed9b12e9-40cf-48d9-bae3-1899b84d5d3e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.6, "x": 0.3, "y": 0.45 }, "kind": "framework", "text": "Comparison of existing therapy vs Nuvalent therapy in normal vs mutated kinase scenarios", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74c19bb8-73d9-4491-82f2-22b390ae8502", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.07, "y": 0.56 }, "kind": "paragraph", "text": "Structural innovations designed to overcome drug-resistance due to kinase mutations", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a71e5f84-a406-4773-8c17-4367b5ca7829", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.17, "x": 0.07, "y": 0.42 }, "kind": "title", "text": "Kinase Resistance", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "255ac126-8c38-43bd-bc45-436e2bd783c7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "38a8d6aa-4ad3-4082-ae89-2e6ea02ae249", "evidence": "paragraph/paragraph: Structural innovations designed to overcome drug-resistance due to kinase mutations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.727095+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "3c5ae9b2-ec04-46fa-9d5f-7303c4904b54", "evidence": "Contrasts the state of 'existing therapy' failure against 'Nuvalent therapy' success in the context of mutation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:38.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "before-after-bridge" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Problem", "beatId": "65550cb5-ee81-4f95-bbe3-0e8a0687e1c8", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 7: Problem statement - Structural innovations designed to overcome drug-resistance due to kinase mutations", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "title": "Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 5, "textChars": 301, "nDataPoints": 0, "notes": "Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:38.618+00", "seconds": 2.763, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/8", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-8", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.6, "x": 0.35, "y": 0.15 }, "kind": "diagram", "text": "Comparison of non-selective vs selective therapy mechanisms", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da7e6888-b040-487d-90a1-7550bc67db27", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.22, "x": 0.66, "y": 0.07 }, "kind": "legend", "text": "SELECTIVE NUVALENT THERAPY", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b343d7a-c64c-4e30-9d0f-a9a4cba14319", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.22, "x": 0.41, "y": 0.07 }, "kind": "legend", "text": "NON-SELECTIVE THERAPY", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "560e92c7-976e-471a-8056-ba0a5065b5d8", "parentComponentId": null }, { "bbox": { "h": 0.13, "w": 0.31, "x": 0.07, "y": 0.57 }, "kind": "paragraph", "text": "Structural innovations designed to increase selectivity to potentially minimize therapy-limiting adverse events related to off-target inhibition AND drive more durable responses", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28310fcc-3dde-4d4c-bd51-ef830bff0ace", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.215, "x": 0.07, "y": 0.42 }, "kind": "title", "text": "Kinase Selectivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a067454-0df9-4f76-b0d6-6b5d148314c2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0c6867bf-82da-4641-bb34-f4995ee6f365", "evidence": "diagram/other: Comparison of non-selective vs selective therapy mechanisms", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.790989+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0c832cbf-22c1-4e98-a29c-94d2c33a12df", "evidence": "Visual side-by-side comparison of two therapeutic approaches", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:38.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "title": "The slide uses a list of icons to represent key clinical attributes of the drug candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 4, "textChars": 276, "nDataPoints": 0, "notes": "The slide uses a list of icons to represent key clinical attributes of the drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.435+00", "seconds": 3.183, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/9", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-9", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.05, "x": 0.512, "y": 0.24 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61f860bb-c3d1-408b-83a1-7ea9d7432052", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.35, "x": 0.58, "y": 0.24 }, "kind": "list", "text": "Active against wild-type ROS1 fusions\nActive against treatment-emergent ROS1 resistance mutations: G2032R, D2033N, L2026M, S1986Y/F\nBrain penetrant\nTRK sparing to minimize CNS adverse events", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1f130ea-1ca5-480e-9b60-3046f1923bbc", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.512, "y": 0.188 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80fab480-936a-46dc-af64-545d87c5f97d", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.33, "x": 0.106, "y": 0.325 }, "kind": "title", "text": "NVL-520 for ROS1-Positive Advanced NSCLC and other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.435+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9045094-f05f-4ac5-8d2d-91f342ce7324", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "resolution", "title": "The table segments patients into kinase inhibitor naïve and those with 1 prior inhibitor, further sub-segmented by mutation type (G2032R vs Non-G2032R).", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 348, "nDataPoints": 5, "notes": "The table segments patients into kinase inhibitor naïve and those with 1 prior inhibitor, further sub-segmented by mutation type (G2032R vs Non-G2032R).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.656+00", "seconds": 3.263, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/10", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-10", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.015, "w": 0.435, "x": 0.076, "y": 0.901 }, "kind": "source-note", "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e36a399-771c-49cf-bc37-18f8463fb3de", "parentComponentId": null }, { "bbox": { "h": 0.515, "w": 0.864, "x": 0.068, "y": 0.285 }, "kind": "table", "text": "Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83686516-3c1d-4a1c-b2b8-d0e6641e1a28", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.695, "x": 0.076, "y": 0.188 }, "kind": "title", "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6031f80-21ba-44e4-abc8-5cf6a955adfb", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.415, "x": 0.076, "y": 0.115 }, "kind": "title", "text": "ROS1-positive NSCLC Market Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db3454c1-26b0-402f-8044-8665d6f699c3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "04b8175b-2096-438a-b3d9-88440fa24f94", "evidence": "table/data: Line of therapy, Sub-population, Incidence (US), CNS disease, Standard of care (2022)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.887996+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Market Sizing", "beatId": "1bb8c0b5-57e2-4bb0-9d13-ed06ee6a7e1a", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slide 10: ROS1-positive NSCLC Market Overview", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "setup", "title": "The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 343, "nDataPoints": 20, "notes": "The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.861+00", "seconds": 3.244, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/11", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-11", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.045, "w": 0.855, "x": 0.076, "y": 0.865 }, "kind": "disclaimer", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-520. Clinical investigation of NVL-520 is ongoing.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc821116-8d8f-413c-9474-2b5b74e4c066", "parentComponentId": null }, { "bbox": { "h": 0.605, "w": 0.862, "x": 0.069, "y": 0.25 }, "kind": "table", "text": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 criteria.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41dd9bab-1336-4426-8ccf-f4513cf1772f", "parentComponentId": null }, { "bbox": { "h": 0.063, "w": 0.191, "x": 0.076, "y": 0.115 }, "kind": "title", "text": "NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34c55c45-ae25-4edb-a887-11dbe22f2f68", "parentComponentId": null }, { "bbox": { "h": 0.026, "w": 0.505, "x": 0.076, "y": 0.188 }, "kind": "title", "text": "Differentiated Product Candidate for ROS1-positive NSCLC Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a3aaf80-8873-4916-9f5d-8112724f81ba", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9ec700cc-ed64-4de6-a729-abd6041a02a6", "evidence": "table/data: Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 criteria.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.954103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "1f6251ff-1208-4845-a800-a95cf462103c", "evidence": "The slide presents a structured grid comparing a lead product candidate against competitors across specific attributes.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:39.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_table" } ], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "tension", "title": "The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 6, "textChars": 647, "nDataPoints": 0, "notes": "The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.994+00", "seconds": 3.37, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/12", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-12", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.025, "w": 0.3, "x": 0.44, "y": 0.18 }, "kind": "callout", "text": "TRK INHIBITION SAFETY IMPLICATIONS", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee19a05d-d6cc-4fc6-91bb-ee50a05f4d92", "parentComponentId": null }, { "bbox": { "h": 0.9, "w": 0.25, "x": 0.73, "y": 0.07 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f41fbc92-8e10-4b75-95a1-18b84d4f1141", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.44, "y": 0.22 }, "kind": "list", "text": "TRKB: Impairments in memory, learning and nociception; Development of obesity caused by hyperphagia and hyperdipsia. TRKC: Impairment of motor neuron afferents and loss of dorsal root ganglia neurons; Defect in proprioception. TRKA: CIPA; Neuropathies.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa7f289c-6b94-444b-a14b-4fb2eff1e79d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.34, "x": 0.07, "y": 0.36 }, "kind": "paragraph", "text": "ROS1 and ALK both share strong structural similarities to TRK. Brain penetration is needed to address associated CNS disease in ROS1 and ALK driven cancers. Inhibitors must be highly selective to avoid CNS toxicities from off-target inhibition of TRK", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc23b5e8-236b-4c13-a42b-c72207b7b32e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.89 }, "kind": "source-note", "text": "Sources: Adapted from Cocco, Scaltriti and Drilon Nat Rev Clin Oncol 2018", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ebf2786-f6ea-44a5-9655-9f7b683be00c", "parentComponentId": null }, { "bbox": { "h": 0.13, "w": 0.34, "x": 0.07, "y": 0.21 }, "kind": "title", "text": "Overcoming Kinase Selectivity in NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97fac04c-c048-4ea2-aea3-30a9983a1885", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "aee419b0-211d-418b-aff6-18702ded8a5d", "evidence": "paragraph/paragraph: ROS1 and ALK both share strong structural similarities to TRK.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.018966+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "65aac5b7-e703-47fe-855e-79b350b26916", "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions", "position": 0, "objective": "What is the cost of not addressing drug resistance in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:38:44.020746+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "evidence", "title": "The slide uses dot plots to show IC50 values for different drugs across fusion partners and mutations, and a bar chart to show tumor regression efficacy.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 486, "nDataPoints": 30, "notes": "The slide uses dot plots to show IC50 values for different drugs across fusion partners and mutations, and a bar chart to show tumor regression efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.656+00", "seconds": 2.992, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/13", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-13", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.28, "x": 0.67, "y": 0.35 }, "kind": "chart", "text": "In vivo efficacy tumor regression bar chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93739a7b-a831-4a4c-b92d-fcefe3300c5b", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.36, "y": 0.35 }, "kind": "chart", "text": "Resistance Mutations IC50 dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c8f2fdf-7158-4180-92b4-98a467d4eb57", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.08, "y": 0.35 }, "kind": "chart", "text": "Fusion Partners IC50 dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0a8d092-04e1-4506-8f59-c581a08873ab", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.07, "y": 0.88 }, "kind": "paragraph", "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PDC, patient-derived cell line", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33dba006-e112-45f1-b1f9-13c782d62f05", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.07, "y": 0.91 }, "kind": "source-note", "text": "Sources: Drilon A. et al., Cancer Discov (2023) 13 (3): 598–615.; Tangpeerachaikul, A. et al., AACR 2022; Deshpande, A. et al., EORTC-NCI-AACR 2021; Pelish, H.E. et al., AACR 2021.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71d6e06c-8cc7-41dd-8a4d-1359be948155", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-520 Exhibits Potent Activity Across Diverse ROS1 Fusion Partners and Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.656+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f661e23-811c-4d6a-8217-1f08151ea1d1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "c1adb716-9384-4bba-9e43-f1e970435869", "evidence": "chart/bar-vertical: In vivo efficacy tumor regression bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.085148+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "81ad9521-ac58-449d-a266-66db47ad14c1", "evidence": "chart/dot: Resistance Mutations IC50 dot plot", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.117342+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "resolution", "title": "The chart on the right uses a log scale for the y-axis to visualize selectivity indices.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 632, "nDataPoints": 10, "notes": "The chart on the right uses a log scale for the y-axis to visualize selectivity indices.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.349+00", "seconds": 2.683, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/14", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-14", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.48, "x": 0.42, "y": 0.35 }, "kind": "chart", "text": "Selectivity Index for ROS1 vs TRK across multiple inhibitors", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e627b98e-74f4-4044-8d09-52cf5c124250", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.09, "y": 0.38 }, "kind": "chart", "text": "Unbound brain:plasma ratio for NVL-520 vs Lorlatinib", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb1a1b28-3b8e-4a1d-943a-a972dd08be75", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.07, "y": 0.88 }, "kind": "source-note", "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies. Sources: Drilon A. et al., Cancer Discov (2023) 13 (3): 598–615.; Tangpeerachaikul, A. et al., EORTC-NCI-AACR 2021; Data on file.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fff5cce5-88c7-40a2-9da1-89f10b51291e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-520 is a Brain Penetrant, ROS1-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd6597a4-3bd6-4bcb-8349-ca19b043b98d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "dd89f82e-245e-45fc-8d12-0d521488c7d4", "evidence": "chart/bar-grouped: Selectivity Index for ROS1 vs TRK across multiple inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.182863+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "9d768201-cb04-4f51-9d4f-35270825b7d9", "evidence": "chart/bar-vertical: Unbound brain:plasma ratio for NVL-520 vs Lorlatinib", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:18.216267+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a side-by-side comparison framework to delineate the two phases of the clinical trial.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 701, "nDataPoints": 0, "notes": "The slide uses a side-by-side comparison framework to delineate the two phases of the clinical trial.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:40.183+00", "seconds": 3.503, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/15", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-15", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.85, "x": 0.07, "y": 0.9 }, "kind": "disclaimer", "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor; a Patients with baseline concurrent oncogenic drivers identified on subsequent testing and patients without measurable disease are excluded from efficacy evaluation per prespecified protocol analysis plan.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e46ef5f-08a1-474f-99f9-95d9df4068b4", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.43, "x": 0.5, "y": 0.2 }, "kind": "framework", "text": "Phase 2: Status Open and Enrolling", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a120346-7e41-4bae-a81d-775387c8f983", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.43, "x": 0.07, "y": 0.2 }, "kind": "framework", "text": "Phase 1: Dose Escalation", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2b9de0e-c8a7-4cc4-aae9-17b6e8bc4c50", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.08, "y": 0.3 }, "kind": "list", "text": "Phase 1 objectives and patient criteria", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09669611-e42c-4a29-b107-b22957b13b75", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.51, "y": 0.35 }, "kind": "list", "text": "Phase 2 objectives and patient criteria", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d583e2dc-4460-424b-86cd-f25c821ffd13", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "ARROS-1 First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "864a24c8-01a7-4ddf-82ce-38fac24247d3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "51b1150b-6902-462a-aec2-054989d30106", "evidence": "Side-by-side layout comparing Phase 1 and Phase 2 trial parameters.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:40.183+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "comparison-frame" } ], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "analysis", "title": "The slide details the patient population (N=35) and the subset of response-evaluable patients (N=21) across five dose cohorts.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 255, "nDataPoints": 20, "notes": "The slide details the patient population (N=35) and the subset of response-evaluable patients (N=21) across five dose cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.795+00", "seconds": 3.075, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/16", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-16", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.85, "x": 0.07, "y": 0.35 }, "kind": "diagram", "text": "Flow diagram showing initial enrollment, back-fill additions, and response-evaluable population breakdown.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.795+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ff3fac6-0ddd-4024-ac13-efd86c04bfbe", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.21 }, "kind": "paragraph", "text": "All-Treated Population (N = 35)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.795+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25ec4a29-e51c-4d77-a9a9-a70591bd9307", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.85 }, "kind": "source-note", "text": "Data as of 13 Sep 22... Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.795+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bee9cdac-67f7-4781-bf4d-5f020b9a1a51", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "Cohort Accrual | ARROS-1 Phase 1 Dose-Escalation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.795+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "751c10af-7796-4065-9d26-f94f205202a4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "analysis", "title": "The data highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 3, "textChars": 594, "nDataPoints": 30, "notes": "The data highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.551+00", "seconds": 2.723, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/17", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-17", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.45, "x": 0.07, "y": 0.78 }, "kind": "source-note", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. All data shown as n (%) unless otherwise specified. CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Categories are not mutually exclusive. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.551+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ac492e9-3639-42f3-8885-1800a6c07c0b", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.85, "x": 0.07, "y": 0.2 }, "kind": "table", "text": "Patient characteristics and treatment history table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.551+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4d42eef-b999-4931-816b-5430a7cce795", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "ARROS-1 Phase 1 Population | Heavily Pretreated ROS1+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.551+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3378f72-0ec4-43d4-a102-fe29d794e7b7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0c0dce42-2003-41e2-b808-0fb0d319e703", "evidence": "table/data: Patient characteristics and treatment history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:18.346036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "analysis", "title": "Data as of 13 Sep 22. N=35 patients.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 602, "nDataPoints": 24, "notes": "Data as of 13 Sep 22. N=35 patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:40.182+00", "seconds": 3.26, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/18", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-18", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.08, "y": 0.33 }, "kind": "list", "text": "No DLTs\nNo treatment-related SAEs\nNo AEs leading to dose reduction or discontinuation\nNo treatment-related dizziness", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fac89b46-98b4-4772-a92a-e31fea2f5cbb", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.08, "y": 0.85 }, "kind": "source-note", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. AE, adverse event; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; DLT, dose-limiting toxicity; SAE, serious adverse event. a Including oedema and oedema peripheral. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "104b0426-da0e-4fd7-afda-b7471a07bcda", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.52, "x": 0.397, "y": 0.258 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in >1 Patient All Treated Patients (N = 35)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab7d9c35-9a93-4fb7-bdf9-65f1e2fae01e", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Safety Profile | Favorable and Consistent with the Highly ROS1-Selective, TRK-Sparing Design of NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea81d95f-0cf3-42ff-ad68-bf0a64401843", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a6935f66-e6d5-4bf7-b351-3e73ba546ab0", "evidence": "table/data: Treatment-Related Adverse Events (TRAEs) in >1 Patient All Treated Patients (N = 35)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.746382+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "evidence", "title": "The chart displays dose-dependent exposure over 24 hours, with horizontal dashed lines representing efficacy targets for different ROS1 variants in CNS and peri", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 4, "textChars": 607, "nDataPoints": 4, "notes": "The chart displays dose-dependent exposure over 24 hours, with horizontal dashed lines representing efficacy targets for different ROS1 variants in CNS and periphery.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.772+00", "seconds": 2.547, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/19", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-19", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.45, "x": 0.08, "y": 0.27 }, "kind": "chart", "text": "NVL-520 concentration over time by dose cohort", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "390adb91-c5a2-4eb0-971d-d884154fdaa2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.08, "y": 0.83 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. Pharmacokinetic data for 125 mg QD cohort are not shown due to immaturity. CNS, central nervous system; h, hours; PK, pharmacokinetics; QD, once daily; SD, standard deviation.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d86521f8-7d68-4ef1-9425-44b881591e9d", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.58, "y": 0.28 }, "kind": "list", "text": "NVL-520 exposure exceeded target levels that provide regression in preclinical models. Favorable pharmacokinetics: Low intra-cohort patient PK variability, Exposure increasing with increasing dose level, Half-life of approximately 20h supports QD dosing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cf7ef31-f5d0-4280-8c74-9b0ea24ebccf", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Pharmacokinetics | NVL-520 Exposure Exceeded Predicted Efficacy Thresholds", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f60a33b-3a52-474b-98db-fc65a671576d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "58b599fe-3d64-4933-8ab4-d404f133acdf", "evidence": "chart/line: NVL-520 concentration over time by dose cohort", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:17.832424+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "evidence", "title": "Clinical trial data table showing efficacy metrics for NVL-520.", "function": "analyze_data", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 3, "textChars": 264, "nDataPoints": 25, "notes": "Clinical trial data table showing efficacy metrics for NVL-520.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:39.223+00", "seconds": 1.998, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/20", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-20", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.82 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22... Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.223+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c6c388f-380d-4a53-a197-b8a867e6eb8d", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.85, "x": 0.07, "y": 0.24 }, "kind": "table", "text": "Table showing patient counts and response rates (ORR, PR, SD, PD, NE) across 5 patient cohorts.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.223+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04fcd033-c546-4b8e-be1d-531d6598b644", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Efficacy | NVL-520 Induced Tumor Response Across Heavily Pretreated Patient Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:39.223+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5209293-ae0c-4d8e-9f00-83f4a6889623", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b20d9084-a3d4-4f63-8a0f-2cefcd033a4d", "evidence": "table/data: Table showing patient counts and response rates (ORR, PR, SD, PD, NE) across 5 patient cohorts.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:17.918395+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 13, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "b738a8c4-d910-4ec1-a962-02c70cd13fd0", "evidence": "Slides 13-20 present preclinical and clinical trial results for NVL-520", "position": 1, "objective": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:38:44.061917+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "evidence", "title": "Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 385, "nDataPoints": 17, "notes": "Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.617+00", "seconds": 5.323, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/21", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-21", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.75, "x": 0.17, "y": 0.2 }, "kind": "chart", "text": "Waterfall plot of best % change in target lesions", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51e94633-ab1a-4500-b4a6-437a1ab57704", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.86 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b93df954-e8ec-47ad-a2e1-7499c3f9f7d1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.07, "y": 0.27 }, "kind": "legend", "text": "Dose level color key", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb3d3c71-4bcc-45a1-879e-354d0bca921e", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.85, "x": 0.07, "y": 0.65 }, "kind": "table", "text": "Patient characteristics table including dose level, prior TKI, and prior lines of therapy", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b59a056f-3e24-4aa2-a170-d93b74f46075", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Efficacy | Radiographic Tumor Regression Observed Across All NVL-520 Dose Levels", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b708ca03-472f-4827-b86f-91b03d100b61", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8fe818ab-c533-45bb-9846-78042b84d805", "evidence": "chart/waterfall: Waterfall plot of best % change in target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:18.005564+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 22, "type": "evidence", "title": "Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 620, "nDataPoints": 6, "notes": "Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.514+00", "seconds": 5.912, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/22", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-22", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.65, "x": 0.07, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot of treatment duration by patient", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.514+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdaf54a9-61cf-4d0b-828b-aa087284a4c7", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.08, "y": 0.87 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.514+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a94d0e1-55f5-4dbb-bb6b-d6e4ddc3aae6", "parentComponentId": null }, { "bbox": { "h": 0.21, "w": 0.22, "x": 0.71, "y": 0.36 }, "kind": "legend", "text": "Legend for treatment types, response status, and ongoing status", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.514+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee125b56-6978-4b29-b781-d8e60c9d01dc", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.43, "y": 0.64 }, "kind": "list", "text": "76% (16/21) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.6 (1.0, 8.3+) months; No treatment discontinuation due to toxicity; Median (range) time to response: 3.6 (3.1, 4.6) weeks", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.514+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bebd7a66-dfea-4964-8f24-285d3b9be422", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "Time on Treatment | Sustained Duration with Follow-up Ongoing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.514+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8873622a-45e4-4a50-802a-220d4a34961c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "evidence", "title": "Includes a spider plot (target lesion change) and a bar chart (allele clearance).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 619, "nDataPoints": 18, "notes": "Includes a spider plot (target lesion change) and a bar chart (allele clearance).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:45.43+00", "seconds": 7.624, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/23", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-23", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.48, "w": 0.25, "x": 0.69, "y": 0.22 }, "kind": "chart", "text": "Reduction in ROS1 G2032R Allele", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b3ee416-f9b5-4057-be2a-b58a45402074", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.31, "x": 0.36, "y": 0.22 }, "kind": "chart", "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8e51839-ded3-4a13-b2f6-32346af86b17", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.85 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e96d995-8bb4-4a82-aed5-2e950da572cf", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.45, "y": 0.74 }, "kind": "legend", "text": "Each unique color indicates data from the same patient across both figures; PD (due to new lesions); Prior treatments include repotrectinib.", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4442375-e88e-499a-a498-3f9a9114624d", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.07, "y": 0.25 }, "kind": "list", "text": "Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5798265b-fe06-42bf-89ce-af0e0a4b7993", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "ROS1 Resistance Mutations | NVL-520 Induced Rapid Responses in TKI-Resistant Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff3c1347-7e12-4d28-91ad-8a5320e3fe5b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 24, "type": "evidence", "title": "Includes patient case study with longitudinal MRI scans.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 477, "nDataPoints": 3, "notes": "Includes patient case study with longitudinal MRI scans.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:40.5+00", "seconds": 2.668, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/24", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-24", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.35, "x": 0.07, "y": 0.75 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22... Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "338d6ff1-aabc-4417-889e-01b6d81441cf", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.5, "x": 0.43, "y": 0.21 }, "kind": "image", "text": "MRI scan series showing baseline, 4 weeks, and 8 weeks", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0988aaa0-5368-48a4-bcb0-ba51ec1009cc", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.35, "x": 0.07, "y": 0.25 }, "kind": "list", "text": "Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases; ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases; No CNS progression observed in any of the 35 treated patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7cf7d6c8-a077-4d02-9e13-f8293f3d938b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.5, "x": 0.43, "y": 0.82 }, "kind": "subtitle", "text": "Intracranial response in 65-year-old female with CD74-ROS1 fusion NSCLC...", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e54165e-3f48-4865-b11e-a1070282073a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "CNS Activity | NVL-520 Induced Responses in Intracranial Lesions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9acaf976-a53d-4f3f-a2a9-101543dea5da", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 25, "type": "evidence", "title": "The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.", "function": "illustrate_case", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 1391, "nDataPoints": 6, "notes": "The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.54+00", "seconds": 4.27, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/25", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-25", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.88 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22. CT, computed tomography; MRI, magnetic resonance imagine; NSCLC, non-small cell lung cancer; PD, Progressive Disease; QD, once daily; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. Images courtesy of Alexander Drilon, Memorial Sloan Kettering Cancer Center. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8bf2dc2c-7e07-4430-8e21-d9c481817011", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.53, "x": 0.43, "y": 0.21 }, "kind": "image", "text": "Medical imaging panels (CT and MRI) showing tumor regression over time.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36833b8f-a1bc-4db1-b506-44c92c5ec5e5", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.35, "x": 0.07, "y": 0.21 }, "kind": "list", "text": "Diagnosis: EZR-ROS1 fusion NSCLC; Entrectinib (~9 months, ROS1 G2032R found on PD); Repotrectinib (~8 weeks); Platinum-based chemo + bevacizumab + entrectinib (Administered for PD, ~8 weeks, primary PD, G2032R still present); NVL-520 (50 mg QD)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "02f70b20-a03c-44db-92a3-362478b91202", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.32, "x": 0.1, "y": 0.55 }, "kind": "paragraph", "text": "PR (-38% by RECIST 1.1) at 4 weeks: right occipital lobe metastasis contraction, decrease in several liver/lung metastases. Further disease regression (-58%) at 16 weeks, near-complete resolution of brain lesion. Treatment well-tolerated without dizziness, orthostasis, or paresthesia. Continues to receive NVL-520 with ongoing response at 5.3 months", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9169d76b-f500-4e00-946e-407c94af134d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.53, "x": 0.43, "y": 0.78 }, "kind": "source-note", "text": "Upper panel: CT indicating segment 5/6 and 3 liver metastases with continuous regression over the course of treatment. Lower panel: MRI demonstrating right occipital lobe metastasis that decreased in size at week 4 and became barely appreciable at week 16.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f7c496f-30a3-4846-861a-98bbdbc5047b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Case Study | Intracranial and Extracranial Activity in TKI-Refractory ROS1 G2032R+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7ba5a2d-5de1-4ae6-8d42-90f62080589b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "33eddfb5-0077-4b16-affc-67cfcf58d750", "evidence": "Chronological treatment history list", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:42.54+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "timeline-item" } ], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 26, "type": "resolution", "title": "Slide 26 of a pitch deck.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 976, "nDataPoints": 0, "notes": "Slide 26 of a pitch deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.542+00", "seconds": 3.18, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/26", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-26", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.65, "x": 0.076, "y": 0.885 }, "kind": "disclaimer", "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose. Source: Adapted from Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4d0c666-3f0a-47d5-93f4-e19beb2fc446", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.85, "x": 0.076, "y": 0.58 }, "kind": "list", "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population, with responses observed in patients: with and without ROS1 G2032R resistance; who progressed through lorlatinib or repotrectinib; with brain metastases.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b026920-18c0-4c07-a0bb-507aef281dd2", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.85, "x": 0.076, "y": 0.305 }, "kind": "list", "text": "In the ongoing ARROS-1 Phase 1 dose-escalation, a wide dose range resulted in exposures exceeding predicted efficacy thresholds without indication of off-target toxicity. NVL-520 has been well tolerated with no DLTs. No dose reductions or treatment discontinuations.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "637f6b40-768b-4be3-9414-83ca408d1c04", "parentComponentId": null }, { "bbox": { "h": 0.075, "w": 0.85, "x": 0.076, "y": 0.145 }, "kind": "title", "text": "NVL-520 is a brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5d1dbec-41f4-4720-9205-041bd99bafb9", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.576, "x": 0.076, "y": 0.105 }, "kind": "title", "text": "OCTOBER 2022 CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.542+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c475683-cfe2-4ddb-a9f2-80807e2a815f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 27, "type": "evidence", "title": "Includes clinical trial data cut-offs and patient enrollment numbers.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 76, "componentCount": 6, "textChars": 1155, "nDataPoints": 4, "notes": "Includes clinical trial data cut-offs and patient enrollment numbers.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.94+00", "seconds": 3.568, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/27", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-27", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.48, "x": 0.439, "y": 0.8 }, "kind": "callout", "text": "ARROS-1 update expected at a medical meeting in 2024", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d02f1016-a5e2-4db3-ad66-1782f75399d2", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.34, "x": 0.082, "y": 0.238 }, "kind": "diagram", "text": "Preliminary Phase 1 Dose Escalation Data: Data cut-off: September 13, 2022 35 ROS1+ patients enrolled across five dose levels (25 mg QD – 125 mg QD) Source: Drilon et al., EORTC-NCI-AACR 2022\nUpdated Phase 1 Data Shared with FDA: Data cut-off: May 17, 2023 87 ROS1+ patients enrolled across six dose levels (25 mg QD – 150 mg QD)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41cbc433-66cd-4f35-b7ea-ea9b24e3e401", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.075, "y": 0.895 }, "kind": "disclaimer", "text": "CNS, Central Nervous System; MTD, Maximum Tolerated Dose; QD, Once Daily.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d530348-4a6d-41cc-b153-7971d10b7455", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.48, "x": 0.439, "y": 0.285 }, "kind": "list", "text": "Overall, the company believes these findings to be consistent with the preliminary Phase 1 conclusions reported in October 2022\nFavorable tolerability of NVL-520 was observed across all dose levels to date\nMTD was not reached, and no clinically significant exposure-response relationships for safety and efficacy were observed across the dose levels evaluated (25 mg – 150 mg daily)\nThe dose level of 100 mg daily maintained steady state plasma levels above all target efficacy thresholds (ROS1 wild type and ROS1 G2032R in both the periphery and in the CNS)\nAlignment with FDA on RP2D selection", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "732b492f-a8b7-46ac-a37b-442ddaa82214", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.35, "x": 0.439, "y": 0.238 }, "kind": "paragraph", "text": "Rationale for Selection of 100 mg as RP2D", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2626d18d-415e-47ce-9a8e-56fff9f49ce9", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.86, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "100 mg QD Selected as Recommended Phase 2 Dose (RP2D) for NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.94+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce79d6df-87ac-40e9-8a16-47b7fbd53741", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 28, "type": "evidence", "title": "The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 6, "textChars": 908, "nDataPoints": 5, "notes": "The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.517+00", "seconds": 4.014, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/28", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-28", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.2, "x": 0.07, "y": 0.43 }, "kind": "list", "text": "NVL-520 dose escalation complete: 25 mg QD – 150 mg QD; RP2D selected: 100 mg QD", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21fb8219-549c-4490-a999-006064970656", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.68, "x": 0.25, "y": 0.66 }, "kind": "paragraph", "text": "Phase 2 cohorts were designed to support potential registration in ROS1-positive NSCLC that is either kinase inhibitor naive or previously treated. Primary Objective: ORR by blinded, independent central review. Secondary Objectives: Additional efficacy measures.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e999443-6be9-4e72-bd83-d2f615332050", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.85 }, "kind": "source-note", "text": "Approximate cohort size, subject to change; Either crizotinib or entrectinib; Platinum-based chemotherapy with or without immunotherapy; With initial TKI of either crizotinib or entrectinib; Includes NSCLC who do not qualify for any of the other cohorts.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90ba595d-a3bc-4962-a223-f9abd4e58bf6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.68, "x": 0.25, "y": 0.3 }, "kind": "table", "text": "Cohort 2a-2e details including N, tumor type, treatment status, and prior therapy", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ddb75b9b-e2bd-47a1-a428-669762e64ba2", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.85, "x": 0.07, "y": 0.18 }, "kind": "title", "text": "Phase 2 ongoing with global enrollment planned across sites in North America, Europe, Asia and Australia", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af750044-3cda-421c-9a1b-015c26996d2a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "ARROS-1 First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f339c335-c337-453f-9665-9a0960a9aa82", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 29, "type": "resolution", "title": "The slide uses a list of icons to define the TPP.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 392, "nDataPoints": 1, "notes": "The slide uses a list of icons to define the TPP.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.486+00", "seconds": 3.878, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/29", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-29", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.555, "w": 0.058, "x": 0.512, "y": 0.267 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7511662f-212f-4edd-933b-a83ef66ccc17", "parentComponentId": null }, { "bbox": { "h": 0.585, "w": 0.365, "x": 0.585, "y": 0.245 }, "kind": "list", "text": "Active against wild-type ALK fusions\nActive against treatment-emergent ALK G1202R single and compound resistance mutations e.g., G1202R/L1196M, G1202R/G1269A, G1202R/L1198F\nBrain penetrant ~30 – 40% of patients with ALK-positive NSCLC present with brain metastases\nTRK sparing to minimize CNS adverse events", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d34f19d1-605e-4ed9-865f-ea4cd22fcc3a", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.251, "x": 0.512, "y": 0.188 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b9cb615-38fb-4a78-93b5-748381243c77", "parentComponentId": null }, { "bbox": { "h": 0.711, "w": 0.331, "x": 0.106, "y": 0.328 }, "kind": "title", "text": "NVL-655 for ALK-Positive Advanced NSCLC and Other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ec0c9cb9-227f-4d8f-841e-c522256f2dff", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 30, "type": "resolution", "title": "The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 49, "componentCount": 4, "textChars": 458, "nDataPoints": 8, "notes": "The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.811+00", "seconds": 3.165, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/30", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-30", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.6, "x": 0.07, "y": 0.89 }, "kind": "source-note", "text": "Sources: Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.811+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fad04bfe-fa76-435e-bf1d-22f16bc2af26", "parentComponentId": null }, { "bbox": { "h": 0.62, "w": 0.86, "x": 0.07, "y": 0.26 }, "kind": "table", "text": "Table showing patient segments by line of therapy, mutation, incidence, CNS disease, and standard of care.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.811+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d37c65ee-e86b-43b4-b6b1-f75fe8fe72e7", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.75, "x": 0.07, "y": 0.18 }, "kind": "title", "text": "Emerging Resistance Mutations and Increasing CNS Involvement Limit Utility of Approved Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.811+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91d76579-d71c-4de7-8912-94e755d8e5eb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "ALK-Positive NSCLC Market Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.811+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76921b2c-e5e1-42b4-a51e-d87e564d7994", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 31, "type": "setup", "title": "The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 355, "nDataPoints": 25, "notes": "The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.113+00", "seconds": 2.443, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/31", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-31", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.85, "x": 0.076, "y": 0.845 }, "kind": "disclaimer", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-655. Clinical investigation of NVL-655 is ongoing.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9acc210-4dbb-4894-881c-d637096f4eaa", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.85, "x": 0.076, "y": 0.27 }, "kind": "table", "text": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f79b130-b8ab-4697-8a2a-3d7e5c8bd2e8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.19, "x": 0.076, "y": 0.115 }, "kind": "title", "text": "NVL-655", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f69ab633-2349-466c-bb11-986cc4943d26", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.53, "x": 0.076, "y": 0.188 }, "kind": "title", "text": "Differentiated Product Candidate for ALK-positive NSCLC patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b7caf63-f5f7-41d5-b14d-5e76b0973457", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6e7a0e43-7037-410f-a0d6-a86271a66d51", "evidence": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:34:22.458103+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "aaa78935-adb7-4c93-99a1-f4fcb2bf0113", "evidence": "Grid-based comparison of product features against competitors", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:41.113+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "comparison_table" } ], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 32, "type": "evidence", "title": "The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 380, "nDataPoints": 20, "notes": "The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:44.813+00", "seconds": 6.064, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/32", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-32", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.3, "x": 0.5, "y": 0.335 }, "kind": "chart", "text": "In vivo tumor regression bar chart comparing Vehicle, Lorlatinib, and NVL-655", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4a53605-cf2b-4a8e-bb54-ab3246a83162", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.38, "x": 0.08, "y": 0.335 }, "kind": "chart", "text": "In vitro IC50 scatter plot comparing NVL-655 to other inhibitors", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f70b046-0f18-480d-95ce-ef0ddcff2259", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.82, "y": 0.48 }, "kind": "paragraph", "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PO, orally; QD, once daily; v, EML4 breakpoint variant.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ed18a6f-8aa2-4540-9e02-a38b71fd014b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.82, "y": 0.85 }, "kind": "source-note", "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36a05f68-73cb-4371-80db-66150741676f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-655 Inhibited Diverse ALK Fusions and Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8964f34f-d3c1-4256-9f76-7d4344998924", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "64a791cd-34bf-4b63-acf8-fccda1093873", "evidence": "In vivo tumor regression bar chart comparing Vehicle, Lorlatinib, and NVL-655", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:22.544326+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 33, "type": "resolution", "title": "The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 513, "nDataPoints": 2, "notes": "The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.883+00", "seconds": 3.065, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/33", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-33", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.22, "x": 0.09, "y": 0.38 }, "kind": "chart", "text": "Brain penetrance comparison between Lorlatinib and NVL-655", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.883+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6000773e-e286-43e0-8d79-d1b36e43b1d3", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.25, "x": 0.36, "y": 0.36 }, "kind": "chart", "text": "Selectivity index for ALK over TRKB", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Scatter plot", "slug": "scatter", "status": "active", "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2", "version": 1, "description": null }, "framework": null }, "subkind": "scatter", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.883+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fbfc6b46-3289-423a-befa-32bcf9afda62", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.09, "y": 0.75 }, "kind": "paragraph", "text": "Wistar Han rats, 10 mg/kg, single dose PO, 1 hour timepoint", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.883+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b4eaf66-8fc9-4cfc-8b56-631e645b8af4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.07, "y": 0.87 }, "kind": "source-note", "text": "CNS, central nervous system; IC50, half-maximal inhibitory concentration; PO, orally; pTRKB, BDNF-stimulated TRKB phosphorylation. Mizuta, H. et al. WCLC-IASLC 2022; Tangpeerachaikul, A. et al. AACR-NCI-EORTC 2021; Pelish, H. et al. AACR 2021.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.883+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e33e940-e87c-4d7d-b4a3-f46bce59a8ba", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-655 is Brain-Penetrant and ALK-Selective, with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.883+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2fe48d7-1472-48ca-9ea1-ef06da22a9d2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "7a88634f-476c-4f97-8db2-21f6c4cf2a7b", "evidence": "In vitro IC50 scatter plot comparing NVL-655 to other inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:22.630075+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 34, "type": "setup", "title": "The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 489, "nDataPoints": 0, "notes": "The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:45.155+00", "seconds": 6.246, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/34", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-34", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.4, "x": 0.07, "y": 0.25 }, "kind": "list", "text": "Phase 1 Dose-Escalation: Patient Population and Objectives", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f5eab7e-dfd5-48ef-816c-6f6988ce1120", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.42, "y": 0.72 }, "kind": "paragraph", "text": "Phase 2 Objectives: Primary (ORR) and Secondary (DOR, TTR, CBR, PFS, OS, intracranial activity, safety, PK)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91eb6cb4-1630-437a-9102-ef2e6c99a750", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.07, "y": 0.82 }, "kind": "source-note", "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb36d4a9-799e-4fc5-9413-3a4883db9779", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.42, "y": 0.25 }, "kind": "table", "text": "Open-Label Phase 2 Cohorts (Planned) table with columns: Cohort, Tumor Type, Prior ALK TKI, Prior Chemo/I-O", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c06fec21-187c-400e-8463-8f8e9d41e634", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "ALKove-1: A Global First-in-Human Phase 1/2 Study of NVL-655 in Patients with Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f9224a2-4ee3-4065-8a95-a28c6250d60a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "88ad70a3-dad0-4482-afe5-820896f76479", "evidence": "Structured presentation of study phases, cohorts, and objectives.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:26:45.155+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "frameworkName": "clinical-trial-design" } ], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 35, "type": "analysis", "title": "The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 364, "nDataPoints": 30, "notes": "The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.079+00", "seconds": 3.087, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/35", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-35", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.85, "x": 0.07, "y": 0.25 }, "kind": "diagram", "text": "Flow diagram showing BOIN dose-escalation, expansion, and response-evaluable population counts.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b071f94-60a9-41ab-ac84-7a020863b436", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.19 }, "kind": "paragraph", "text": "All-Treated Population (N = 93)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91cabeeb-cbf1-404b-9852-484d9822c7b8", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.082 }, "kind": "source-note", "text": "Data cut-off: 8 Aug 2023. BOIN, Bayesian optimal interval design; mg, milligram; NSCLC, non-small cell lung cancer; QD, once daily. a First response evaluation is pending for 27 patients...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fc1dbbb-5f57-47e6-acdc-51dce11b1bb9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "Cohort Accrual | ALKOVE-1 Phase 1 Dose-Escalation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b32b56d5-bb2a-43a7-9db7-b01f7397cbdf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "596f8754-9649-42c2-937e-0396439d93cc", "evidence": "The slide uses a flow-based diagram to show the progression of patient cohorts through different trial stages.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:42.079+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "process" } ], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 36, "type": "analysis", "title": "Clinical trial baseline characteristics table.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 3, "textChars": 700, "nDataPoints": 30, "notes": "Clinical trial baseline characteristics table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:41.86+00", "seconds": 2.621, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/36", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-36", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.45, "x": 0.07, "y": 0.77 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. All data shown as n (%) unless otherwise specified. 1G, 1st generation ALK TKI; 2G, 2nd generation ALK TKI; 3G, 3rd generation ALK TKI; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Cis-allelic configuration not confirmed in all cases. c Categories are not mutually exclusive. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.86+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "469760f9-772b-44ea-804b-02decdfd74db", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.86, "x": 0.07, "y": 0.205 }, "kind": "table", "text": "Patient characteristics and treatment history table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.86+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "931e9ba1-e3ae-4aa2-b2f0-7a672e49da8f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "ALKOVE-1 Phase 1 Population | Heavily Pretreated ALK+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:41.86+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f26df68-768c-459a-8dcd-b1717de54ea6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 37, "type": "analysis", "title": "Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 4, "textChars": 1195, "nDataPoints": 32, "notes": "Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.523+00", "seconds": 4.048, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/37", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-37", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.07, "y": 0.83 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CPK, creatinine phosphokinase; DLT, dose-limiting toxicity; TRAE, treatment-related adverse event. a TRAEs resulting in treatment discontinuation were Grade 4 ALT/Grade 3 AST elevations (50 mg QD) and intolerable Grade 2 constipation (occurred at 100 mg QD following dose increase from 50 mg QD). b TRAEs resulting in dose-reduction were Grade 2 ALT/AST elevation (50 mg), Grade 3 ALT/AST elevation (100 mg), Grade 2 nausea/cognitive disturbance (150 mg), Grade 4 CPK elevation (200 mg), and Grade 3 neutropenia (200 mg). Treatment continues at the reduced dose for 4 of these 5 patients. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58338d70-d8f1-486b-ac8f-0eeb72ea5a61", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.07, "y": 0.28 }, "kind": "list", "text": "MTD has not been identified; 1 DLT: transient asymptomatic Grade 4 CPK increase. Infrequent TRAEs requiring dose modification: 2% discontinued, 5% dose-reduced. Profile consistent with avoiding TRK-related neurotoxicities.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1244f7b5-22e7-4a20-ac94-1fda80b08b2e", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.5, "x": 0.42, "y": 0.25 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Table columns: Grade 1, Grade 2, Grade ≥3, Any Grade.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa5bbd0b-2112-4f74-9266-196df3b24f57", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Safety Profile | Favorable and Consistent with ALK-Selective, TRK-Sparing Design of NVL-655", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8166b41-5249-4d80-9808-b8c598d34e12", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 38, "type": "analysis", "title": "The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 919, "nDataPoints": 5, "notes": "The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.876+00", "seconds": 3.183, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/38", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-38", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.55, "x": 0.08, "y": 0.22 }, "kind": "chart", "text": "NVL-655 Pharmacokinetics at Steady State (Day 15)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.876+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c829171-b8cd-46f9-8647-9e763306bfd2", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.3, "x": 0.65, "y": 0.28 }, "kind": "list", "text": "Favorable pharmacokinetics: Low intra-cohort variability, Dose proportional exposure, Half-life supports QD dosing. Dose levels >= 50 mg QD may provide increased coverage of single and compound mutations in the CNS.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.876+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05fb79e1-9847-4b25-9a79-3ab5104eb3bd", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.7, "x": 0.07, "y": 0.83 }, "kind": "source-note", "text": "Available data for patients enrolled as of 08 Aug 23. Pharmacokinetic data for 200 mg QD cohort are not shown due to immaturity. CNS, central nervous system; h, hours; PK, pharmacokinetics; QD, once daily; SD, standard deviation. a Based on >= 100% tumor growth inhibition (best response) in in vivo models bearing HIP1-ALK, Ba/F3 EML4-ALK v1 G1202R, EML4-ALK v3 G1202R/L1196M, and Ba/F3 EML4-ALK v1 I1171N, respectively, divided by predicted human CNS Kp (brain to plasma ratio). Targets for CNS exceed corresponding periphery values. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.876+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e5d9942-0064-4665-93bc-cdccc939385f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Pharmacokinetics | NVL-655 Exposure Achieved Predicted Efficacy Thresholds", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.876+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e86a85e-07ff-48f1-9379-4411940c896e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 39, "type": "evidence", "title": "The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK muta", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 546, "nDataPoints": 23, "notes": "The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.997+00", "seconds": 3.206, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/39", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-39", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.85, "x": 0.07, "y": 0.22 }, "kind": "callout", "text": "100% clearance observed in 14/16 patients with centrally confirmed ALK G1202R or I1171X mutations, of whom 13 had received prior lorlatinib", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd36bd51-1784-4f77-a64f-1d22cbdbbac3", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.85, "x": 0.07, "y": 0.35 }, "kind": "chart", "text": "Clearance of ALK Mutations Detected in Plasma", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d66820bf-da89-4435-a870-9aec768cc75c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.07, "y": 0.85 }, "kind": "disclaimer", "text": "Pt, Patient. Data are shown for all treated patients with ALK mutations detected on Cycle 1 Day 1 and with at least one follow-up assessment. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55aa9119-e998-46a4-97af-3f5d7ec0a6d6", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.3, "x": 0.56, "y": 0.335 }, "kind": "legend", "text": "G1202R Mutation, I1171X (X = N or T) Mutation, Other Mutation, Received prior lorlatinib", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f501446e-e43e-4cce-ae8c-4e879f14f396", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Pharmacodynamics | NVL-655 Induced Clearance of Diverse ALK Resistance Mutation Alleles", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65319a82-3caa-4db5-a05f-e23485f0f8b9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3839ecf4-dd08-4d23-ac9f-b6ad983f0cc9", "evidence": "Clearance of ALK Mutations Detected in Plasma", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:22.931747+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 40, "type": "evidence", "title": "The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 3, "textChars": 1177, "nDataPoints": 64, "notes": "The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.049+00", "seconds": 3.172, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/40", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-40", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.86, "x": 0.07, "y": 0.75 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. Response-evaluable patients with ALK+ NSCLC. 1G, 1st generation ALK TKI (crizotinib); 2G, 2nd generation ALK TKI (alectinib, brigatinib, or ceritinib); CNS, central nervous system; NE, not evaluable; ORR, objective response rate; PD, progressive disease, PR, partial response, RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease, TKI, tyrosine kinase inhibitor. a Out of 16 patients harboring presumed compound ALK mutations, 8 have evidence of cis-allelic configuration by central ctDNA analysis. b Includes patients with single G1202R mutation (n=5) and G1202R with compound mutations (n=12; 6 with evidence of cis-allelic configuration). c Includes 4 patients with ongoing partial responses pending confirmation. d Three patients discontinued treatment due to clinical progression without post-baseline radiographic assessment. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.049+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01da0a5d-2691-431b-8e5b-cbfa51133dac", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.86, "x": 0.07, "y": 0.23 }, "kind": "table", "text": "Table showing ORR and Best Response (PR, SD, PD, NE) for various patient cohorts including ALK resistance mutations and prior TKI history.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.049+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1fce75e1-7f8a-4ddf-9849-525b2c021edf", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Activity | NVL-655 Induced Tumor Response Across Heavily Pretreated Patient Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.049+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c6714a0-741d-4776-9bb0-c7890969a142", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 41, "type": "evidence", "title": "Clinical trial data visualization showing ORR and best percentage change in target lesions.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 373, "nDataPoints": 51, "notes": "Clinical trial data visualization showing ORR and best percentage change in target lesions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.48+00", "seconds": 2.534, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/41", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-41", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.82, "x": 0.14, "y": 0.25 }, "kind": "chart", "text": "Waterfall plot of tumor response", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "852cb095-184e-4f88-84f8-055de001529f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.06, "y": 0.86 }, "kind": "disclaimer", "text": "Data cut-off: 8 August 2023. Response-evaluable patients with NSCLC. ALK mutation as per any prior local testing or central baseline ctDNA analyses.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "210b4f49-8b64-4f78-9b02-0e4d7cac2686", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.1, "x": 0.06, "y": 0.31 }, "kind": "legend", "text": "Dose level legend (15-200 mg QD)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b2916c6-3ed4-4023-bd64-666cb6ef9f53", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.9, "x": 0.06, "y": 0.65 }, "kind": "table", "text": "Dose level and prior therapy history table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1cf8b5f4-72ba-4a79-9867-86e521e786f1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Activity | Radiographic Tumor Response Observed in Patients With and Without Known ALK Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.48+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35691bea-d892-477f-b166-2a4bccd6675b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b772db01-226a-42f4-b3f4-590040855188", "evidence": "Waterfall plot of tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:23.061257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 42, "type": "evidence", "title": "The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 646, "nDataPoints": 4, "notes": "The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:46.802+00", "seconds": 6.781, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/42", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-42", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.55, "x": 0.07, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot of patient treatment duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0857bb10-8c68-4378-a7fc-5d10e1ad510f", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.07, "y": 0.89 }, "kind": "disclaimer", "text": "Data as of 8 August 2023, for response-evaluable patients with NSCLC. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3642055-c7bb-48f9-adf1-aa33a61afa74", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.65, "y": 0.28 }, "kind": "legend", "text": "Legend for patient cohorts and clinical events (PR, PD, Ongoing)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cb4fc38-b438-4ee2-84d9-6829399df7ff", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.45, "x": 0.46, "y": 0.63 }, "kind": "list", "text": "All patients with RECIST 1.1 tumor response remain on treatment without disease progression; 67% (34/51) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.4 (0.3, 12.3) months; Median (range) time to response: 6.1 (5.1, 12.3) weeks", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2584b48-1754-48a9-9960-dd9047711274", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "Time on Treatment | Sustained Duration with Follow-up Ongoing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41bfc55e-6a80-49c8-ac90-edea759bb4c4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fa1b8c13-1632-439a-91c0-3099b338aeed", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:28.943337+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 42, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 43, "type": "evidence", "title": "Includes two patient case studies with MRI scans showing tumor reduction.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 6, "textChars": 848, "nDataPoints": 4, "notes": "Includes two patient case studies with MRI scans showing tumor reduction.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.153+00", "seconds": 3.119, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/43", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-43", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.7, "x": 0.07, "y": 0.88 }, "kind": "disclaimer", "text": "Data as of 8 August 2023. CNS, central nervous system; CR, complete response; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a974a85c-e4a4-4953-83b9-32cf5dcc50e7", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.18, "x": 0.29, "y": 0.33 }, "kind": "image", "text": "MRI scans showing baseline and 12 weeks for complete response case", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2be14d76-80cf-42a2-b290-aa757788cd23", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.18, "x": 0.73, "y": 0.33 }, "kind": "image", "text": "MRI scans showing baseline and 6 weeks for partial response case", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1e417b0-fb0e-4c9e-8042-a6ded0f1f7ae", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.08, "y": 0.25 }, "kind": "list", "text": "Intracranial Complete Response in EML4-ALK fusion NSCLC: EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases; Treatment continues at 4.2 months", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9bd91de-7880-4eac-a56b-7cca8dd425d4", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.53, "y": 0.25 }, "kind": "list", "text": "Intracranial Partial Response in ALK L1196Q NSCLC: EML4-ALK fusion NSCLC with ALK L1196Q resistance mutation; 3 lines of therapy; NVL-655 (150 mg QD); CNS PR after ~6 weeks; Treatment continues at 3.7 months", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca33a885-221e-467a-a616-e39151d8f1c9", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "CNS Activity | NVL-655 Induced Intracranial Responses in Patients with TKI-Refractory ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f7e0b95-27b0-4ee5-81e4-bb46f1ff16a8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 44, "type": "appendix", "title": "Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.", "function": "illustrate_case", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 6, "textChars": 900, "nDataPoints": 4, "notes": "Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.736+00", "seconds": 3.553, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/44", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-44", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.48, "x": 0.46, "y": 0.65 }, "kind": "chart", "text": "ALK Allele Fraction Best % Change from Baseline", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9be4293c-fd9c-490d-bfb6-ad525b6d1e9d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.48, "x": 0.46, "y": 0.275 }, "kind": "image", "text": "Baseline and 20 weeks CT scans", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d3624e2-ea06-4f78-81da-3a77dd1a444d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.38, "x": 0.08, "y": 0.52 }, "kind": "list", "text": "Complete clearance of ALK mutant alleles in ctDNA by 6 weeks; Partial Response by RECIST 1.1 (-36%) at 6 weeks, confirmed and persisting (-62%) at 20 weeks; Treatment well tolerated; Continues to receive NVL-655 for ~5 months with an ongoing PR", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83443f6a-2d48-42c5-ac71-6fa0d3159ac4", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.38, "x": 0.08, "y": 0.22 }, "kind": "paragraph", "text": "Diagnosis: EML4-ALK v3/b NSCLC with ALK mutations G1202R, G1269A, and I1322M. Prior treatments: 8 prior lines of therapy, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and platinum-based chemo. Sites of disease: Including lung, liver, and CNS.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31be3ea5-c518-4878-8b31-a38ad7812e48", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.07, "y": 0.89 }, "kind": "source-note", "text": "Data as of 8 August 2023. CNS, central nervous system; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2470ff4-24f4-4d21-bbbe-4245d93f9a3e", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Case Study | NVL-655 Induced Response in a TKI-Refractory Patient with ALK G1202R/G1269A Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.736+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ae006bd-518c-4df9-8315-c1c877706c23", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before-After-Bridge", "slug": "before-after-bridge", "status": "active", "bestFor": null, "canonId": "019dd956-8604-7188-883f-42370288ad05", "version": 1, "bodyDocId": null, "description": "Narrative structure: Paint the before, show the after, explain the bridge", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "a4a8fdb0-6970-4bde-98c7-146078e5ab61", "evidence": "Baseline and 20 weeks CT scans", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.037817+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 44, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 45, "type": "resolution", "title": "The slide uses a hierarchical bulleted list to summarize clinical trial conclusions.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 1025, "nDataPoints": 1, "notes": "The slide uses a hierarchical bulleted list to summarize clinical trial conclusions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:49.15+00", "seconds": 8.931, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/45", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-45", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.28, "w": 0.86, "x": 0.07, "y": 0.41 }, "kind": "list", "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population with ALK+ NSCLC, with responses observed in patients: with and without diverse single and compound ALK resistance mutations, who have exhausted available therapies, including those who have received 2nd generation ALK TKI(s), lorlatinib, and chemotherapy, and with brain metastases.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "224db69e-e8fe-4961-a940-87ad86b71f35", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.81 }, "kind": "list", "text": "Phase 1 is ongoing to further understand the safety profile, PK, and preliminary efficacy, and determine the RP2D", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e1e3360-b9cc-4da6-af2c-b3d0d73756ea", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.86, "x": 0.07, "y": 0.28 }, "kind": "list", "text": "In the ongoing ALKOVE-1 Phase 1 dose-escalation, NVL-655 was well tolerated. Emerging safety profile was consistent with ALK-selective, TRK-sparing design.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a49751d0-c7c5-4b1d-aea5-1459b64f089b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.75 }, "kind": "list", "text": "Dose levels ≥ 50 mg QD may provide increased coverage of single and compound mutations in the CNS", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f61bcdb3-b63b-4539-8fdd-f9f13a29e1dc", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.07, "y": 0.91 }, "kind": "source-note", "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53a6c218-aedb-424f-9e4d-83d412b3ea98", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.13 }, "kind": "title", "text": "NVL-655 is a brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bbbb7a0c-a1f9-4035-aa1f-168616d1a846", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:49.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70cb4199-864b-4b43-a781-84999524de0f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "AIDA Model", "slug": "aida-model", "status": "active", "bestFor": null, "canonId": "019dd956-86fc-773c-813f-d416714b8413", "version": 1, "bodyDocId": null, "description": "Attention, Interest, Desire, Action - classic persuasion sequence", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "c75ec5d2-d5d1-4c81-9d66-515cb102c593", "evidence": "This preliminary dataset indicates encouraging clinical activity... with responses observed in patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:34:29.10207+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 45, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Traction", "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465", "matchId": "da906df9-65a8-4cdd-a2aa-90d9295193c0", "beatType": null, "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 46, "type": "resolution", "title": "The slide uses a clear, icon-based list to define the therapeutic profile.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 6, "textChars": 288, "nDataPoints": 2, "notes": "The slide uses a clear, icon-based list to define the therapeutic profile.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:46.218+00", "seconds": 5.887, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/46", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-46", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.41, "w": 0.058, "x": 0.512, "y": 0.335 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd95097a-8ea4-42f1-9930-d9105028c147", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.586, "y": 0.682 }, "kind": "list", "text": "Brain penetrant. ~19% of patients with HER2-positive NSCLC present with brain metastases", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "719bcb04-33a7-47c9-87ec-75db81410bcc", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.33, "x": 0.586, "y": 0.494 }, "kind": "list", "text": "EGFR sparing. Related adverse events include skin rash and diarrhea", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df17d73d-4150-4633-a92c-79529b8d1d6f", "parentComponentId": null }, { "bbox": { "h": 0.024, "w": 0.28, "x": 0.586, "y": 0.362 }, "kind": "list", "text": "Active against HER2 and HER2ex20", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fcc2c5d5-4a76-4e6a-b889-4a08df9e926f", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.37, "x": 0.107, "y": 0.311 }, "kind": "title", "text": "NVL-330 for Malignancies Driven by HER2 Exon 20 Insertion Mutations (HER2ex20)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83893054-1fea-4dc9-b34d-8187e80c5f1f", "parentComponentId": null }, { "bbox": { "h": 0.026, "w": 0.252, "x": 0.512, "y": 0.233 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:46.218+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9991f881-6ed1-49b4-a9bf-33259d950a87", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 47, "type": "resolution", "title": "The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 489, "nDataPoints": 15, "notes": "The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:43.028+00", "seconds": 2.637, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/47", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-47", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.31, "x": 0.39, "y": 0.22 }, "kind": "chart", "text": "AVOIDING EGFR INHIBITION", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49613355-1f3a-4e84-8877-574f6c6df9fb", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.21, "x": 0.72, "y": 0.22 }, "kind": "chart", "text": "BRAIN PENETRANCE", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7f8d1b2-e218-4a49-9e22-e6eb7473e86e", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.31, "x": 0.07, "y": 0.22 }, "kind": "chart", "text": "IN VITRO ACTIVITY, HER2 AND HER2ex20", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f6ed1a0-74cf-4545-b5aa-1f477106b69a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.86, "x": 0.07, "y": 0.88 }, "kind": "disclaimer", "text": "IC50, half-maximal inhibitory concentration; PO, orally; Head-to-head clinical studies comparing NVL-330 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies Source: Andrews K.L. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f09d814e-52e3-4941-bc26-af17fca1805d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-330 is a Brain Penetrant, HER2ex20-Selective Kinase Inhibitor with Potential to Avoid Adverse Events Related to EGFR Inhibition", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:43.028+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "abdb5ff8-9e97-4030-aacd-75aa220e3c4b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "6ffab56d-b5d0-478b-8a6d-e72f32e7fb9f", "evidence": "IN VITRO ACTIVITY, HER2 AND HER2ex20, AVOIDING EGFR INHIBITION, BRAIN PENETRANCE", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.201644+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 47, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 48, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 26, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:42.482+00", "seconds": 1.967, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/48", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-48", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.13, "x": 0.076, "y": 0.748 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0bc467a6-792e-4279-bead-67902934ed45", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.36, "x": 0.076, "y": 0.45 }, "kind": "title", "text": "Pipeline Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:42.482+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8fe051e-a4b9-431f-ba5f-e14b2b4216eb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 49, "type": "appendix", "title": "The slide uses a hexagonal process flow to illustrate the company's strategic methodology.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 711, "nDataPoints": 0, "notes": "The slide uses a hexagonal process flow to illustrate the company's strategic methodology.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:44.425+00", "seconds": 3.718, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/49", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-49", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.4, "x": 0.23, "y": 0.05 }, "kind": "image", "text": "Three-step hexagonal process flow", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43a71660-6d61-4224-9169-122b3ee74ee5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.45, "y": 0.12 }, "kind": "list", "text": "Close Partnership with Physician-Scientists: Characterize emerging medical needs for patients; Refine understanding of safety events observed with currently available multi-kinase inhibitors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d40cee9-1577-42e2-9f2c-163b31433b67", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.65, "y": 0.68 }, "kind": "list", "text": "Disciplined Program Advancement: Well defined selection criteria; Focused resource deployment on opportunities with potential for immediate impact", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c16fadfe-84ce-4bae-a759-d193d833818c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.54, "y": 0.036 }, "kind": "list", "text": "Rigorous Target Selection: Combine clinical insights with internal expertise in chemistry and structure-based drug design and development; Prioritize opportunities with an aim to maximize patient impact through more selective kinase inhibitor design", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff2e56d9-76f6-4c70-8bd5-e8b26f2e7625", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.07, "y": 0.54 }, "kind": "title", "text": "Rigorous Target Selection and Disciplined Advancement of Discovery Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8008d84a-b201-48ad-be7f-254944c2a536", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.07, "y": 0.4 }, "kind": "title", "text": "Pipeline Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edec1433-0c60-4cba-a957-9f62f13e9b4c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "94e0cd6a-c200-4139-af31-8e3a40f1287b", "evidence": "Three-step hexagonal process flow", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:34:29.30019+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 49, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "af407c93-b346-4f54-add0-d67a7fd0ec9b", "evidence": "Sequential hexagonal flow diagram", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:26:44.425+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 49, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 50, "type": "resolution", "title": "The slide uses a Gantt-style visualization to represent clinical trial progress.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 340, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to represent clinical trial progress.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:44.025+00", "seconds": 3.178, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/50", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-50", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.25, "x": 0.35, "y": 0.35 }, "kind": "chart", "text": "Clinical trial progress bars for NVL-520, NVL-655, and NVL-330.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee718aa5-08e8-418b-a940-35f9e2a0b028", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.86, "x": 0.07, "y": 0.25 }, "kind": "framework", "text": "Pipeline development timeline", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f51b7064-fe0d-4441-9ca1-4a5d6589c932", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.8, "x": 0.07, "y": 0.18 }, "kind": "paragraph", "text": "Advancing parallel lead programs in ROS1-positive and ALK-positive NSCLC, and multiple early-stage discovery programs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34d06d9c-c390-46bb-8d47-d1baa19d4f01", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.86, "x": 0.07, "y": 0.25 }, "kind": "table", "text": "Pipeline table with columns for Indication, Candidate, Mutation, Phase, Milestones, and Rights.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3bd4e97e-f8da-4cf5-8fb3-0f46ca8e3f3f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.07, "y": 0.1 }, "kind": "title", "text": "Nuvalent Pipeline – Ongoing Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f47438b6-6837-4f04-9157-d2fec278b05d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b4f65386-a8c4-47a3-ac0e-4a67852b4b88", "evidence": "Visual representation of project phases over time for multiple programs.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:26:44.025+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 50, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 51, "type": "setup", "title": "Slide 51 of a pitch deck.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 7, "textChars": 656, "nDataPoints": 0, "notes": "Slide 51 of a pitch deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:44.902+00", "seconds": 3.359, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/51", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-51", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.025, "w": 0.39, "x": 0.102, "y": 0.88 }, "kind": "callout", "text": "Expected cash runway into second half of 2025", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da2bda32-2b47-41ed-a9d1-ba882dc33d11", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.27, "x": 0.7, "y": 0.15 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af486b8a-8d0e-46f6-bb74-b52f5beebb9d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.53, "x": 0.102, "y": 0.33 }, "kind": "list", "text": "Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery. Potential for differentiated inhibition of proven kinase targets.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94e37114-d065-459f-916b-8a4f37ec23c1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.53, "x": 0.102, "y": 0.515 }, "kind": "list", "text": "Parallel lead clinical programs in ROS1-positive and ALK-positive NSCLC: RP2D selected for NVL-520; Preliminary data update from ALKOVE-1 for NVL-655.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a30b82ed-c0bb-4656-a62f-e5123bb13cdd", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.53, "x": 0.102, "y": 0.74 }, "kind": "paragraph", "text": "Robust development pipeline leveraging established approach: HER2ex20 inhibitor NVL-330 progressing through IND-enabling studies, with additional discovery research programs ongoing.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "582ad1d2-77f2-4f5f-b24e-23a2813211bd", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.495, "x": 0.082, "y": 0.23 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d76d15b-45a9-42b4-893a-8984857b5da3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.28, "x": 0.166, "y": 0.096 }, "kind": "title", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.902+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aba84f87-d1ee-45d6-9b98-a210679574ea", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "92fb98c5-d289-4fe8-9bb7-6dd980761457", "evidence": "Robust development pipeline leveraging established approach", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:29.397271+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 51, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 52, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 5, "textChars": 107, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:26:44.153+00", "seconds": 2.223, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/52", "deck": "/decks/019de076-0bfb-77a4-9766-824e83d61c36", "deckAnchor": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-52", "deckJson": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.25, "x": 0.7, "y": 0.15 }, "kind": "image", "text": "3D molecular structure", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a433b8aa-4233-4ba3-b134-b841e1a16e28", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.33, "x": 0.33, "y": 0.388 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c4dc6c3-6f10-4a90-966c-bdfec1764fbe", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.16, "x": 0.42, "y": 0.55 }, "kind": "paragraph", "text": "www.nuvalent.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72df6a59-cd1f-47e2-ac4a-bb50d03b2d65", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.34, "x": 0.33, "y": 0.85 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "401f689d-80e4-48e6-904a-605a75673b6d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.43, "y": 0.425 }, "kind": "title", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:26:44.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee3134d0-779b-4b67-95bb-fcea73136f01", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "d8270b7f-e511-4554-a797-82fa87d701e4", "evidence": "PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:34:29.461248+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 52, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 7, "to": 7, "label": "Problem", "description": "Slide 7: Problem statement - Structural innovations designed to overcome drug-resistance due to kinase mutations" }, { "from": 6, "to": 6, "label": "Solution", "description": "Slide 6: Solution - Precisely Targeted Therapies for patients with cancer" }, { "from": 10, "to": 10, "label": "Market Sizing", "description": "Slide 10: ROS1-positive NSCLC Market Overview" }, { "from": 13, "to": 45, "label": "Traction", "description": "Slides 13-45: Various traction slides, including preclinical and clinical trial results" } ], "loops": [ { "from": 7, "to": 12, "label": "Cost Of Inaction", "description": "What is the cost of not addressing drug resistance in cancer treatment?" }, { "from": 13, "to": 20, "label": "Hypothesis Test", "description": "Can Nuvalent's therapies demonstrate efficacy in clinical trials?" } ] }